Janus kinase inhibitor; JAK inhibitor

From Aaushi
Jump to navigation Jump to search

Indications

Adverse effects

* boxed warning:

  • risks of serious heart-related events, cancer, blood clots, & death

Mechanism of action

More general terms

More specific terms

Additional terms

References

  1. FDA MedWatch. Safety Information. Sept 1, 2021 Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death. https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk
  2. 2.0 2.1 Harris S JAK Inhibitors Increased VTE Risk in People With Inflammatory Disease Link appears to be soft, but caution advised for higher-risk patients who use agents for extended periods. MedPage Today December 30, 2022 https://www.medpagetoday.com/reading-room/acrr/psoriaticarthritis/102442
    Maqsood MH, Weber BN, Haberman RH et al Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials. ACR Open Rheumatol. 2022 Oct;4(10):912-922 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35903881 PMCID: PMC9555201 Free PMC article https://onlinelibrary.wiley.com/doi/full/10.1002/acr2.11479